Semaglutide, a GLP-1 medication, shows long-term weight loss and cardiovascular benefits for non-diabetic overweight adults in two studies at the European Congress on Obesity.
Semaglutide, a GLP-1 medication, offers weight loss and cardiovascular benefits for non-diabetic adults with overweight for up to four years, according to two studies presented at the European Congress on Obesity. The long-term weight effects of semaglutide are examined in one study, while another investigates whether cardiovascular benefits are related to starting weight or weight lost.
May 13, 2024
3 Articles